| Age and PSA level at diagnosis | Mean (range) |
| Age (years) | 69.9 (47 - 86) |
| PSA (initial, ng/mL) | 666.1 (24.25 - 6334) |
| Clinical characteristics | Number of patients (%) |
| ISUP grade group | 63 (92.6) |
| 1 | 5 (7.9) |
| 2 | 8 (12.7) |
| 3 | 15 (23.8) |
| 4 | 14 (22.2) |
| 5 | 21 (33.3) |
| Paralysis (6 paraplegia* + 1 tetraplegia) | 7 (10.3) |
| Hydronephrosis | 11 (16.2) |
| Hypertension | 15 (22.1) |
| Diabetes | 4 (5.9) |
| Patients’ evolution |
|
| Follow-up data | Mean (range) |
| Follow-up duration (months) | 22.1 (3 - 99) |
| PSA (nadir, ng/mL) | 22.5 (0.01 - 220.25) |
| Time to nadir PSA level | 8.9 (3 - 57) |
| PSA kinetics and deaths | Number of patients (%) |
| PSA < 4 ng/mL in ≤ 12 months | 16 (23.6) |
| Deaths | 19 (27.9) |